Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy

被引:347
|
作者
Sharkey, ME
Teo, I
Greenough, T
Sharova, N
Luzuriaga, K
Sullivan, JL
Bucy, RP
Kostrikis, LG
Haase, A
Veryard, C
Davaro, RE
Cheeseman, SH
Daly, JS
Bova, C
Ellison, RT
Mady, B
Lai, KK
Moyle, G
Nelson, M
Gazzard, B
Shaunak, S
Stevenson, M
机构
[1] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA
[2] Hammersmith Hosp, Imperial Coll, Sch Med, Dept Infect Dis, London W12 0NN, England
[3] Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01605 USA
[4] Univ Alabama, Dept Pathol, Birmingham, AL 35233 USA
[5] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA
[6] Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA
[7] Univ Massachusetts Mem Hlth Care, Div Infect Dis, Worcester, MA 01655 USA
[8] Chelsea & Westminster Hosp, London SW10 9NH, England
关键词
D O I
10.1038/71569
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Treatment of HIV-1-infected individuals with a combination of anti-retroviral agents results in sustained suppression of HIV-1 replication, as evidenced by a reduction in plasma viral RNA to levels below the limit of detection of available assays(1,2). However, even in patients whose plasma viral RNA levels have been suppressed to below detectable levels for up to 30 months, replication-competent virus can routinely be recovered from patient peripheral blood mononuclear cells(3,4) and from semen(5). A reservoir of latently infected cells established early in infection(6) may be involved in the maintenance of viral persistence despite highly active anti-retroviral therapy(.)(3-5) However, whether virus replication persists in such patients is unknown. HIV-1 cDNA episomes are labile products of virus infection and indicative of recent infection events. Using episome-specific PCR, we demonstrate here ongoing virus replication in a large percentage of infected individuals on highly active anti-retroviral therapy, despite sustained undetectable levels of plasma viral RNA. The presence of a reservoir of 'covert' virus replication in patients on highly active antiretroviral therapy has important implications for the clinical management of HIV-1-infected individuals and for the development of virus eradication strategies.
引用
收藏
页码:76 / 81
页数:6
相关论文
共 50 条
  • [1] Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy
    Mark E. Sharkey
    Ian Teo
    Thomas Greenough
    Natalia Sharova
    Katherine Luzuriaga
    John L. Sullivan
    R. Pat Bucy
    Leondios G. Kostrikis
    Ashley Haase
    Claire Veryard
    Raul E. Davaro
    Sarah H. Cheeseman
    Jennifer S. Daly
    Carol Bova
    Richard T. Ellison
    Brian Mady
    Kwan Kew Lai
    Graeme Moyle
    Mark Nelson
    Brian Gazzard
    Sunil Shaunak
    Mario Stevenson
    Nature Medicine, 2000, 6 : 76 - 81
  • [2] The development of tuberculosis in patients receiving highly active anti-retroviral therapy for HIV infection
    Breen, RAM
    Smith, CJ
    Cropley, I
    Johnson, MA
    Lipman, MCI
    THORAX, 2004, 59 (01) : 37 - 37
  • [3] Stochastic modelling of the eradication of the HIV-1 infection by stimulation of latently infected cells in patients under highly active anti-retroviral therapy
    Sanchez-Taltavull, Daniel
    Vieiro, Arturo
    Alarcon, Tomas
    JOURNAL OF MATHEMATICAL BIOLOGY, 2016, 73 (04) : 919 - 946
  • [4] Stochastic modelling of the eradication of the HIV-1 infection by stimulation of latently infected cells in patients under highly active anti-retroviral therapy
    Daniel Sánchez-Taltavull
    Arturo Vieiro
    Tomás Alarcón
    Journal of Mathematical Biology, 2016, 73 : 919 - 946
  • [5] HIV-1 rebound after anti-retroviral therapy
    Ho, DD
    Zhang, LQ
    NATURE MEDICINE, 2000, 6 (07) : 736 - 737
  • [6] HIV-1 rebound after anti-retroviral therapy
    David D. Ho
    Linqi Zhang
    Nature Medicine, 2000, 6 : 736 - 737
  • [7] Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active anti-retroviral therapy in Uganda
    Baalwa, Joshua
    Mayanja-Kizza, Harriet
    Kamya, Moses R.
    John, Laurence
    Kambugu, Andrew
    Colebunders, Robert
    AFRICAN HEALTH SCIENCES, 2008, 8 (03) : 190 - 195
  • [8] Breast Discomfort in HIV Positive Patients Treated with Highly Active Anti-Retroviral Therapy
    Allan, E. G.
    Allan, P. S.
    DRUG SAFETY, 2014, 37 (10) : 846 - 847
  • [9] Changes in immune parameters in HIV-1 infected children during highly active anti-retroviral therapy (HAART).
    Westby, M
    Watkins, AM
    Drake, J
    Wills, B
    Cammack, N
    Sharland, M
    AIDS, 1998, 12 : S95 - S95
  • [10] EFFICACY OF HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY (HAART) IN PATIENTS WITH HBV-HIV CO-INFECTION
    Kosi, L.
    Reiberger, T.
    Rutter, K.
    pfistershammer, K.
    Rieger, A.
    Peck-Radosavljevic, M.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S143 - S143